NCT04711824
Breast Cancer Type: HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: BRCA+
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 1|Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody, Misc Inhibitor, Radiation Therapy, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: 
Exclusions: Patient has more than 10 untreated brain metastases; Patient has symptomatic brain metastases requiring immediate surgical resection; Patient has had prior whole brain radiation therapy
https://ClinicalTrials.gov/show/NCT04711824